Please assess the completion status of the following clinical trial:

Trial Title: Riluzole in the Treatment of Bipolar Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female age 18-65~* Meets DSM-IV criteria for Bipolar Disorder and is currently depressed~* Current score of \>/= 18 on the Hamilton Depression Scale~Exclusion Criteria:~* Active psychotic/manic symptoms~* Lifetime history of schizophrenia or obsessive compulsive disorder~* Clinically significant medical disease~* Women who are pregnant or lactating and women who are not using a medically accepted method of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Riluzole (Type: EXPERIMENTAL): Riluzole 50 mg twice daily for 2 weeks, increased to riluzole 50 mg in the morning and 100 mg in the evening for 1 week if tolerated, with a further increase to riluzole 100 mg twice daily if tolerated for 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).